selegiline has been researched along with Movement Disorders in 15 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 9 (60.00) | 18.7374 |
| 1990's | 4 (26.67) | 18.2507 |
| 2000's | 1 (6.67) | 29.6817 |
| 2010's | 1 (6.67) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Doyu, M; Ibi, T; Niwa, J; Taguchi, S | 1 |
| Bertoni, JM; Hauser, RA; Molho, E; Sethi, KD; Waters, CH | 1 |
| Birkmayer, W; Knoll, J; Riederer, P; Youdim, MB | 1 |
| Barthalmus, GT; Hardin, LK; Thompson, D | 1 |
| Burns, RS; Davis, TL; Roznoski, M | 1 |
| Boonkongchuen, P; Churchyard, A; Lees, AJ; Mathias, CJ | 1 |
| Durif, F | 1 |
| Lander, CM; Lees, A; Stern, G | 1 |
| Antal, J; Antóny, M; Csanaky, A; Csanda, E | 1 |
| Rinne, UK; Siirtola, T; Sonninen, V | 1 |
| Agnoli, A; Baronti, F; Denaro, A; Ruggieri, S; Stocchi, F | 1 |
| Csanda, E; Takáts, A; Tárczy, M | 1 |
| Dubuis, R | 1 |
| Fornadi, F; Ulm, G | 1 |
| Mihatsch, W; Przuntek, H; Russ, H | 1 |
2 review(s) available for selegiline and Movement Disorders
| Article | Year |
|---|---|
Treating and preventing levodopa-induced dyskinesias: current and future strategies.
Topics: Clinical Trials as Topic; Dopamine Agonists; Forecasting; Levodopa; Movement Disorders; Polypharmacy; Receptors, Dopamine D2; Selegiline | 1999 |
'On-off' phenomenon: description, incidence and management.
Topics: Bromocriptine; Dose-Response Relationship, Drug; Humans; Levodopa; Monoamine Oxidase Inhibitors; Movement Disorders; Parkinson Disease; Selegiline | 1987 |
5 trial(s) available for selegiline and Movement Disorders
| Article | Year |
|---|---|
Zydis selegiline reduces off time in Parkinson's disease patients with motor fluctuations: a 3-month, randomized, placebo-controlled study.
Topics: Adult; Aged; Aged, 80 and over; Antiparkinson Agents; Double-Blind Method; Electrocardiography; Female; Humans; Incidence; Male; Middle Aged; Movement Disorders; Parkinson Disease; Selegiline; Severity of Illness Index | 2004 |
Acute effects of COMT inhibition on L-DOPA pharmacokinetics in patients treated with carbidopa and selegiline.
Topics: Aged; Antiparkinson Agents; Benzophenones; Carbidopa; Dose-Response Relationship, Drug; Humans; Levodopa; Movement Disorders; Nitrophenols; Parkinson Disease; Selegiline; Tolcapone | 1995 |
Autonomic effects of selegiline: possible cardiovascular toxicity in Parkinson's disease.
Topics: Aged; Antiparkinson Agents; Cardiovascular Diseases; Drug Therapy, Combination; Female; Humans; Levodopa; Male; Monoamine Oxidase Inhibitors; Movement Disorders; Parkinson Disease; Selegiline | 1997 |
Experiences with L-deprenyl in Parkinsonism.
Topics: Clinical Trials as Topic; Dose-Response Relationship, Drug; Double-Blind Method; Drug Therapy, Combination; Female; Humans; Levodopa; Male; Movement Disorders; Parkinson Disease; Phenethylamines; Selegiline | 1978 |
R-(-)-deprenyl in the treatment of end-of-dose akinesia.
Topics: Aged; Aged, 80 and over; Clinical Trials as Topic; Disability Evaluation; Female; Humans; Levodopa; Male; Middle Aged; Movement Disorders; Parkinson Disease; Phenethylamines; Selegiline | 1987 |
8 other study(ies) available for selegiline and Movement Disorders
| Article | Year |
|---|---|
[Dyskinesia-hyperpyrexia syndrome in a patient with Parkinson's disease: a case report].
Topics: Aged; Benzothiazoles; Delayed-Action Preparations; Drug Substitution; Drug Therapy, Combination; Female; Fever; Humans; Levodopa; Movement Disorders; Parkinson Disease; Pramipexole; Selegiline | 2015 |
(-)-Deprenyl leads to prolongation of L-dopa efficacy in Parkinson's disease.
Topics: Aged; Drug Therapy, Combination; Female; Humans; Levodopa; Male; Movement Disorders; Parkinson Disease; Phenethylamines; Selegiline | 1983 |
MAO-A and -B inhibitors selectively alter Xenopus mucus-induced behaviors of snakes.
Topics: Analysis of Variance; Animals; Behavior, Animal; Clorgyline; Disease Models, Animal; Movement Disorders; Mucus; Selegiline; Snakes; Xenopus laevis | 1993 |
Oscillations in performance in levodopa-treated parkinsonians: treatment with bromocriptine and L-deprenyl.
Topics: Bromocriptine; Dyskinesia, Drug-Induced; Female; Humans; Levodopa; Male; Movement Disorders; Parkinson Disease; Phenethylamines; Selegiline | 1979 |
L-deprenyl treatment of on-off phenomena in Parkinson's disease.
Topics: Aged; Benserazide; Dopamine; Drug Therapy, Combination; Female; Homovanillic Acid; Humans; Hydroxyindoleacetic Acid; Levodopa; Male; Middle Aged; Movement Disorders; Parkinson Disease; Phenethylamines; Selegiline; Vanilmandelic Acid | 1978 |
The role of MAO-b inhibitors in the treatment of Parkinson's disease.
Topics: Adult; Aged; Depression; Drug Therapy, Combination; Female; Humans; Levodopa; Male; Middle Aged; Movement Disorders; Parkinson Disease; Phenethylamines; Selegiline | 1986 |
(-)Deprenyl in the treatment of decompensated Parkinson's disease.
Topics: Benserazide; Drug Combinations; Humans; Hydrazines; Levodopa; Movement Disorders; Parkinson Disease; Phenethylamines; Selegiline | 1986 |
Intracerebroventricular administration of 1-methyl-4-phenylpyridinium ion in mice: effects of simultaneously administered nomifensine, deprenyl, and 1-t-butyl-4,4-diphenylpiperidine.
Topics: 1-Methyl-4-phenylpyridinium; Animals; Brain; Catecholamines; Caudate Nucleus; Dose-Response Relationship, Drug; Drug Interactions; Female; Injections, Intraventricular; Male; Monoamine Oxidase Inhibitors; Movement Disorders; Nomifensine; Phenethylamines; Piperidines; Pyridinium Compounds; Selegiline; Serotonin | 1988 |